Compare Berkshire Hathaway Inc Class B (BRK.B) vs Pfizer Inc (PFE) Price & Performance

BRK.B trades at $529.65, up 1.73% today, with a bullish technical signal from moving averages and oscillators. The stock is near its pivot point of $530, with support at $522 and resistance at $536. Analyst consensus is positive, with 57% of 7 analysts rating it a Buy and none recommending Sell, indicating strong institutional confidence.

The outlook remains favorable given the bullish technicals and analyst support, though overbought RSI readings suggest near-term caution. Key risks include market volatility and macroeconomic pressures, but the stock's strong fundamentals and institutional backing provide a solid foundation for potential growth.

Pfizer (PFE) trades at $27.05, up 1.16% with a bullish technical signal and consistent earnings beats in recent quarters. Revenue remains stable around $62-63 billion, though net income is projected to decline in 2026. The stock shows strong profitability margins and a solid balance sheet, but faces headwinds from patent expirations and competitive pressures.

The outlook is mixed: valuation multiples appear reasonable, and analyst consensus leans hold with a $27.86 target. Key risks include execution on pipeline catalysts and margin compression. Upside depends on successful drug launches and cost management amid a challenging revenue environment.